title: Comparison of results after fluoroquinolones and combination therapies in type IIIA chronic prostatitis.
abstract: OBJECTIVE
  We investigated retrospectively the clinical outcomes of the patients with type iii inflammatory chronic prostatitis, who were treated with fluoroquinolones with and without an α-blocker between 2009-2011.
  
  
  METHODS
  Diagnosis was established with medical history (symptoms presented longer than 3 months within previous 6 months), physical examination, Meares-Stamey test and the questionnaire of the NIH-CPSI. The responses to the treatment were assessed with uroflowmetry test and the questionnaire of NIH-CPSI at initial and after 4 weeks of the treatment. The patients with incomplete data and treatment and who treated with α-blockers and/or antibiotics in the period 4 weeks prior to the therapy started in our clinic and had any surgery of lower urinary tract previously were excluded. The patients were classified under 6 groups; group1=ciprofloxacin, group2=ofloxacin, group3=levofloxacin, group4=ciprofloxacin+tamsulosin, group5=ofloxacin+tamsulosin, group 6=levofloxacin+tamsulosin. Wilcoxon Signed Ranks and Kruskal Wallis test were used for comparison of results. Mann Whitney U test with Bonferroni correction made was used as posthoc (P<.05).
  
  
  RESULTS
  The median scores of NIH-CPSI decreased significantly in all groups (P<.05). Levofloxacin reduced the median total scores of NIH-CPSI more than ciprofloxacin and ofloxacin monotherapies. The combination therapies were better than antibiotic therapies alone and best result was obtained in levofloxacin+tamsulosin combination.
  
  
  CONCLUSIONS
  Tamsulosin+fluoroquinolone (especially tamsulosin+levofloxacin) combinations yielded better results in both NIH-CPSI scores and peak flow rates.
authors.affiliation: Department of Urology, Medical Faculty, Inonu University, Malatya, Turquía. Electronic address: ramazan.altintas@inonu.edu.tr.
authors.forename: R
authors.initials: R
authors.lastname: Altintas
authors.forename: F
authors.initials: F
authors.lastname: Oguz
authors.forename: A
authors.initials: A
authors.lastname: Beytur
authors.forename: C
authors.initials: C
authors.lastname: Ediz
authors.forename: A
authors.initials: A
authors.lastname: Gunes
authors.forename: A
authors.initials: A
authors.lastname: Ozer
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000145:classification / Q000188:drug therapy*; D012189:Retrospective Studies; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D055815:Young Adult
chemical_list: D000317:Adrenergic alpha-Antagonists; D024841:Fluoroquinolones; D013449:Sulfonamides; D000077409:Tamsulosin
keywords: Alpha blocker; Bloqueador alfa; Chronic prostatitis; Fluoroquinolonas; Fluoroquinolones; Prostatitis crónica